US Stock Movement | Bambusa Therapeutics (BBTX.US) debuts on the US stock market, shares drop over 8%
As of press time, the stock is down over 8%, trading at $14.685.
According to Zhihui Finance APP, on Friday, Bambusa Therapeutics (BBTX.US) debuted on the US stock market. As of press time, the stock had fallen more than 8%, trading at $14.685. The IPO price was $16. Bambusa Therapeutics is a Boston-based clinical-stage biopharmaceutical company focused on developing next-generation long-acting bispecific antibody drugs for the treatment of immune system and inflammatory diseases. These drugs are capable of simultaneously targeting two disease-related biological targets, aiming to improve treatment efficacy, extend the duration of action, and reduce the frequency of patient dosing. The company’s leading drug candidate, BBT001, is being developed for the treatment of atopic dermatitis (eczema), chronic spontaneous urticaria, and other skin diseases; another candidate, BBT002, mainly targets asthma, chronic obstructive pulmonary disease, and chronic rhinosinusitis with nasal polyps. In addition, the company is also developing early-stage drugs for inflammatory bowel diseases and autoimmune diseases.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Crypto prices
More
